Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Current Hypertension Reports|May 31, 2024
Hypertension and Cardiovascular Outcomes in Inflammatory and Autoimmune Diseases: A Systematic Review and Meta-analysisMarie Barozet, Olivier Le Tilly, Theodora Bejan-Angoulvant, et al.
Annales De Biologie Clinique|April 19, 2024
[Hormone anti-müllérienne (AMH) en pédiatrie : établissement de valeurs de référence avec le dosage de l'AMH Fujirebio<sup>®</sup> Lumipulse G et comparaison avec le dosage Roche<sup>®</sup> Elecsys sur les mêmes échantillons pédiatriques]Jean-Baptiste Delaye, Olivier Le Tilly, Emmanuel Enard, et al.
Molecular Neurobiology|March 30, 2019
Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: the Missing Link?Bérenger Largeau, Olivier Le Tilly, Bénédicte Sautenet, et al.
British Journal of Clinical Pharmacology|January 19, 2022
Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target-mediated drug disposition modelOlivier Le Tilly, Philippe Gatault, Christophe Baron, et al.
Clinical Pharmacology and Therapeutics|February 6, 2021
Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal AdministrationOlivier Le Tilly, Nicolas Azzopardi, Claire Bonneau, et al.
Clinical Pharmacokinetics|August 14, 2025
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab PharmacokineticsDavid Ternant, Olivier Le Tilly, Guillaume Cartron, et al.
Pharmaceutics|November 27, 2021
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) ModelDavid Ternant, Olivier Le Tilly, Laurence Picon, et al.
Clinical Pharmacokinetics|August 5, 2021
Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition ModelDavid Ternant, Marc Pfister, Olivier Le Tilly, et al.
British Journal of Clinical Pharmacology|February 19, 2024
Eculizumab dose tapering should take into account the nonlinearity of its pharmacokineticsOlivier Le Tilly, Philippe Gatault, Saida Semlali, et al.
Annals of Clinical Biochemistry|February 2, 2018
Post hoc analysis of plasma amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disabilityJean-Baptiste Delaye, Franck Patin, Emmanuelle Lagrue, et al.
Pageof 2